Finally, the panellists were asked whether or not they agreed that patients should be informed about the magnitude of benefit (in terms of overall survival) of interventions with a known small-to-marginal benefit, and be offered no treatment as a reasonable alternative. Predictably, in the present era of “shared decision-making”, 92% of the panellists voted “yes” on this last question.
Posted on
Previous Article
« The right drug for the right patient Next Article
Robot-assisted radical cystectomy or open radical cystectomy? »
« The right drug for the right patient Next Article
Robot-assisted radical cystectomy or open radical cystectomy? »
Table of Contents: BCC 2019
Featured articles
New Prognostic Biomarkers for Survival Breast Cancer
St. Gallen Consensus
Special Lectures
Extrapolating data from clinical trials as we treat patients in real life
What is the clinical benefit of treatment of patients with early breast cancer?
Adjuvant and neoadjuvant therapy: principles and practical considerations
Selected Posters
Discordance of biomarkers in multifocal and lymph node positive breast cancer
New Prognostic Biomarkers for Survival Breast Cancer
Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer
Related Articles
May 21, 2019
Gene expression signatures
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com